Long non-coding RNA PAXIP1-AS1 facilitates cell invasion and angiogenesis of glioma by recruiting transcription factor ETS1 to upregulate KIF14 expression

Gliomas are common life-threatening cancers, mainly due to their aggressive nature and frequent invasiveness and long non-coding RNAs (lncRNAs) are emerging as promising molecular targets. Therefore, we explored the regulatory mechanisms underlying the putative involvement of the lncRNA PAX-interact...

Full description

Saved in:
Bibliographic Details
Published inJournal of experimental & clinical cancer research Vol. 38; no. 1; pp. 486 - 12
Main Authors Xu, Haiyang, Zhao, Guifang, Zhang, Yu, Jiang, Hong, Wang, Weiyao, Zhao, Donghai, Yu, Hongquan, Qi, Ling
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 10.12.2019
BioMed Central
BMC
Subjects
Analysis
Animals
Brain Neoplasms - genetics
Brain Neoplasms - pathology
Cancer
Cell Line, Tumor
Cell Nucleus - genetics
Development and progression
Endothelium
ETS1
Fluorides
Gene expression
Gene Expression Regulation, Neoplastic
Glioma
Glioma - genetics
Glioma - pathology
Gliomas
Health aspects
Human Umbilical Vein Endothelial Cells
Humans
Hybridization
KIF14
Kinesin
Kinesin - genetics
Laboratory animals
Long non-coding RNA
Mice
Migration
Neoplasm Invasiveness
Neoplasm Transplantation
Nervous system
Oncogene Proteins - genetics
Patients
PAXIP1-AS1
Promoter Regions, Genetic
Proteins
Proto-Oncogene Protein c-ets-1 - genetics
RNA
RNA, Long Noncoding - genetics
Surgery
Transcription factors
Tumors
Up-Regulation
China
United States > US
Japan
Angiogenesis
Glioma
Migration
KIF14
PAXIP1-AS1
ETS1
Invasion
Long non-coding RNA
Online AccessGet full text

Cover

Abstract Gliomas are common life-threatening cancers, mainly due to their aggressive nature and frequent invasiveness and long non-coding RNAs (lncRNAs) are emerging as promising molecular targets. Therefore, we explored the regulatory mechanisms underlying the putative involvement of the lncRNA PAX-interacting protein 1- antisense RNA1/ETS proto-oncogene 1/kinesin family member 14 (PAXIP1-AS1/ETS1/KIF14) axis in glioma cell invasion and angiogenesis. Firstly, we identified differentially expressed lncRNA PAXIP1-AS1 as associated with glioma based on bioinformatic data. Then, validation experiments were conducted to confirm a high expression level of lncRNA PAXIP1-AS1 in glioma tissues and cells, accompanied by upregulated KIF14. We further examined the binding between lncRNA PAXIP1-AS1, KIF14 promoter activity, and transcription factor ETS1. Next, overexpression vectors and shRNAs were delivered to alter the expression of lncRNA PAXIP1-AS1, KIF14, and ETS1 to analyze their effects on glioma progression in vivo and in vitro. LncRNA PAXIP1-AS1 was mainly distributed in the nucleus of glioma cells. LncRNA PAXIP1-AS1 could upregulate the KIF14 promoter activity by recruiting transcription factor ETS1. Overexpression of lncRNA PAXIP1-AS1 enhanced migration, invasion, and angiogenesis of human umbilical vein endothelial cells in glioma by recruiting the transcription factor ETS1 to upregulate the expression of KIF14, which was further confirmed by accelerated tumor growth in nude mice. The key findings of this study highlighted the potential of the lncRNA PAXIP1-AS1/ETS1/KIF14 axis as a therapeutic target for glioma treatment, due to its role in controlling the migration and invasion of glioma cells and its angiogenesis.
AbstractList Abstract Background Gliomas are common life-threatening cancers, mainly due to their aggressive nature and frequent invasiveness and long non-coding RNAs (lncRNAs) are emerging as promising molecular targets. Therefore, we explored the regulatory mechanisms underlying the putative involvement of the lncRNA PAX-interacting protein 1- antisense RNA1/ETS proto-oncogene 1/kinesin family member 14 (PAXIP1-AS1/ETS1/KIF14) axis in glioma cell invasion and angiogenesis. Methods Firstly, we identified differentially expressed lncRNA PAXIP1-AS1 as associated with glioma based on bioinformatic data. Then, validation experiments were conducted to confirm a high expression level of lncRNA PAXIP1-AS1 in glioma tissues and cells, accompanied by upregulated KIF14. We further examined the binding between lncRNA PAXIP1-AS1, KIF14 promoter activity, and transcription factor ETS1. Next, overexpression vectors and shRNAs were delivered to alter the expression of lncRNA PAXIP1-AS1, KIF14, and ETS1 to analyze their effects on glioma progression in vivo and in vitro. Results LncRNA PAXIP1-AS1 was mainly distributed in the nucleus of glioma cells. LncRNA PAXIP1-AS1 could upregulate the KIF14 promoter activity by recruiting transcription factor ETS1. Overexpression of lncRNA PAXIP1-AS1 enhanced migration, invasion, and angiogenesis of human umbilical vein endothelial cells in glioma by recruiting the transcription factor ETS1 to upregulate the expression of KIF14, which was further confirmed by accelerated tumor growth in nude mice. Conclusions The key findings of this study highlighted the potential of the lncRNA PAXIP1-AS1/ETS1/KIF14 axis as a therapeutic target for glioma treatment, due to its role in controlling the migration and invasion of glioma cells and its angiogenesis.
Background Gliomas are common life-threatening cancers, mainly due to their aggressive nature and frequent invasiveness and long non-coding RNAs (lncRNAs) are emerging as promising molecular targets. Therefore, we explored the regulatory mechanisms underlying the putative involvement of the lncRNA PAX-interacting protein 1- antisense RNA1/ETS proto-oncogene 1/kinesin family member 14 (PAXIP1-AS1/ETS1/KIF14) axis in glioma cell invasion and angiogenesis. Methods Firstly, we identified differentially expressed lncRNA PAXIP1-AS1 as associated with glioma based on bioinformatic data. Then, validation experiments were conducted to confirm a high expression level of lncRNA PAXIP1-AS1 in glioma tissues and cells, accompanied by upregulated KIF14. We further examined the binding between lncRNA PAXIP1-AS1, KIF14 promoter activity, and transcription factor ETS1. Next, overexpression vectors and shRNAs were delivered to alter the expression of lncRNA PAXIP1-AS1, KIF14, and ETS1 to analyze their effects on glioma progression in vivo and in vitro. Results LncRNA PAXIP1-AS1 was mainly distributed in the nucleus of glioma cells. LncRNA PAXIP1-AS1 could upregulate the KIF14 promoter activity by recruiting transcription factor ETS1. Overexpression of lncRNA PAXIP1-AS1 enhanced migration, invasion, and angiogenesis of human umbilical vein endothelial cells in glioma by recruiting the transcription factor ETS1 to upregulate the expression of KIF14, which was further confirmed by accelerated tumor growth in nude mice. Conclusions The key findings of this study highlighted the potential of the lncRNA PAXIP1-AS1/ETS1/KIF14 axis as a therapeutic target for glioma treatment, due to its role in controlling the migration and invasion of glioma cells and its angiogenesis. Keywords: Long non-coding RNA, PAXIP1-AS1, ETS1, KIF14, Glioma, Migration, Invasion, Angiogenesis
Gliomas are common life-threatening cancers, mainly due to their aggressive nature and frequent invasiveness and long non-coding RNAs (lncRNAs) are emerging as promising molecular targets. Therefore, we explored the regulatory mechanisms underlying the putative involvement of the lncRNA PAX-interacting protein 1- antisense RNA1/ETS proto-oncogene 1/kinesin family member 14 (PAXIP1-AS1/ETS1/KIF14) axis in glioma cell invasion and angiogenesis. Firstly, we identified differentially expressed lncRNA PAXIP1-AS1 as associated with glioma based on bioinformatic data. Then, validation experiments were conducted to confirm a high expression level of lncRNA PAXIP1-AS1 in glioma tissues and cells, accompanied by upregulated KIF14. We further examined the binding between lncRNA PAXIP1-AS1, KIF14 promoter activity, and transcription factor ETS1. Next, overexpression vectors and shRNAs were delivered to alter the expression of lncRNA PAXIP1-AS1, KIF14, and ETS1 to analyze their effects on glioma progression in vivo and in vitro. LncRNA PAXIP1-AS1 was mainly distributed in the nucleus of glioma cells. LncRNA PAXIP1-AS1 could upregulate the KIF14 promoter activity by recruiting transcription factor ETS1. Overexpression of lncRNA PAXIP1-AS1 enhanced migration, invasion, and angiogenesis of human umbilical vein endothelial cells in glioma by recruiting the transcription factor ETS1 to upregulate the expression of KIF14, which was further confirmed by accelerated tumor growth in nude mice. The key findings of this study highlighted the potential of the lncRNA PAXIP1-AS1/ETS1/KIF14 axis as a therapeutic target for glioma treatment, due to its role in controlling the migration and invasion of glioma cells and its angiogenesis.
Gliomas are common life-threatening cancers, mainly due to their aggressive nature and frequent invasiveness and long non-coding RNAs (lncRNAs) are emerging as promising molecular targets. Therefore, we explored the regulatory mechanisms underlying the putative involvement of the lncRNA PAX-interacting protein 1- antisense RNA1/ETS proto-oncogene 1/kinesin family member 14 (PAXIP1-AS1/ETS1/KIF14) axis in glioma cell invasion and angiogenesis.BACKGROUNDGliomas are common life-threatening cancers, mainly due to their aggressive nature and frequent invasiveness and long non-coding RNAs (lncRNAs) are emerging as promising molecular targets. Therefore, we explored the regulatory mechanisms underlying the putative involvement of the lncRNA PAX-interacting protein 1- antisense RNA1/ETS proto-oncogene 1/kinesin family member 14 (PAXIP1-AS1/ETS1/KIF14) axis in glioma cell invasion and angiogenesis.Firstly, we identified differentially expressed lncRNA PAXIP1-AS1 as associated with glioma based on bioinformatic data. Then, validation experiments were conducted to confirm a high expression level of lncRNA PAXIP1-AS1 in glioma tissues and cells, accompanied by upregulated KIF14. We further examined the binding between lncRNA PAXIP1-AS1, KIF14 promoter activity, and transcription factor ETS1. Next, overexpression vectors and shRNAs were delivered to alter the expression of lncRNA PAXIP1-AS1, KIF14, and ETS1 to analyze their effects on glioma progression in vivo and in vitro.METHODSFirstly, we identified differentially expressed lncRNA PAXIP1-AS1 as associated with glioma based on bioinformatic data. Then, validation experiments were conducted to confirm a high expression level of lncRNA PAXIP1-AS1 in glioma tissues and cells, accompanied by upregulated KIF14. We further examined the binding between lncRNA PAXIP1-AS1, KIF14 promoter activity, and transcription factor ETS1. Next, overexpression vectors and shRNAs were delivered to alter the expression of lncRNA PAXIP1-AS1, KIF14, and ETS1 to analyze their effects on glioma progression in vivo and in vitro.LncRNA PAXIP1-AS1 was mainly distributed in the nucleus of glioma cells. LncRNA PAXIP1-AS1 could upregulate the KIF14 promoter activity by recruiting transcription factor ETS1. Overexpression of lncRNA PAXIP1-AS1 enhanced migration, invasion, and angiogenesis of human umbilical vein endothelial cells in glioma by recruiting the transcription factor ETS1 to upregulate the expression of KIF14, which was further confirmed by accelerated tumor growth in nude mice.RESULTSLncRNA PAXIP1-AS1 was mainly distributed in the nucleus of glioma cells. LncRNA PAXIP1-AS1 could upregulate the KIF14 promoter activity by recruiting transcription factor ETS1. Overexpression of lncRNA PAXIP1-AS1 enhanced migration, invasion, and angiogenesis of human umbilical vein endothelial cells in glioma by recruiting the transcription factor ETS1 to upregulate the expression of KIF14, which was further confirmed by accelerated tumor growth in nude mice.The key findings of this study highlighted the potential of the lncRNA PAXIP1-AS1/ETS1/KIF14 axis as a therapeutic target for glioma treatment, due to its role in controlling the migration and invasion of glioma cells and its angiogenesis.CONCLUSIONSThe key findings of this study highlighted the potential of the lncRNA PAXIP1-AS1/ETS1/KIF14 axis as a therapeutic target for glioma treatment, due to its role in controlling the migration and invasion of glioma cells and its angiogenesis.
Background Gliomas are common life-threatening cancers, mainly due to their aggressive nature and frequent invasiveness and long non-coding RNAs (lncRNAs) are emerging as promising molecular targets. Therefore, we explored the regulatory mechanisms underlying the putative involvement of the lncRNA PAX-interacting protein 1- antisense RNA1/ETS proto-oncogene 1/kinesin family member 14 (PAXIP1-AS1/ETS1/KIF14) axis in glioma cell invasion and angiogenesis. Methods Firstly, we identified differentially expressed lncRNA PAXIP1-AS1 as associated with glioma based on bioinformatic data. Then, validation experiments were conducted to confirm a high expression level of lncRNA PAXIP1-AS1 in glioma tissues and cells, accompanied by upregulated KIF14. We further examined the binding between lncRNA PAXIP1-AS1, KIF14 promoter activity, and transcription factor ETS1. Next, overexpression vectors and shRNAs were delivered to alter the expression of lncRNA PAXIP1-AS1, KIF14, and ETS1 to analyze their effects on glioma progression in vivo and in vitro. Results LncRNA PAXIP1-AS1 was mainly distributed in the nucleus of glioma cells. LncRNA PAXIP1-AS1 could upregulate the KIF14 promoter activity by recruiting transcription factor ETS1. Overexpression of lncRNA PAXIP1-AS1 enhanced migration, invasion, and angiogenesis of human umbilical vein endothelial cells in glioma by recruiting the transcription factor ETS1 to upregulate the expression of KIF14, which was further confirmed by accelerated tumor growth in nude mice. Conclusions The key findings of this study highlighted the potential of the lncRNA PAXIP1-AS1/ETS1/KIF14 axis as a therapeutic target for glioma treatment, due to its role in controlling the migration and invasion of glioma cells and its angiogenesis.
Gliomas are common life-threatening cancers, mainly due to their aggressive nature and frequent invasiveness and long non-coding RNAs (lncRNAs) are emerging as promising molecular targets. Therefore, we explored the regulatory mechanisms underlying the putative involvement of the lncRNA PAX-interacting protein 1- antisense RNA1/ETS proto-oncogene 1/kinesin family member 14 (PAXIP1-AS1/ETS1/KIF14) axis in glioma cell invasion and angiogenesis. Firstly, we identified differentially expressed lncRNA PAXIP1-AS1 as associated with glioma based on bioinformatic data. Then, validation experiments were conducted to confirm a high expression level of lncRNA PAXIP1-AS1 in glioma tissues and cells, accompanied by upregulated KIF14. We further examined the binding between lncRNA PAXIP1-AS1, KIF14 promoter activity, and transcription factor ETS1. Next, overexpression vectors and shRNAs were delivered to alter the expression of lncRNA PAXIP1-AS1, KIF14, and ETS1 to analyze their effects on glioma progression in vivo and in vitro. LncRNA PAXIP1-AS1 was mainly distributed in the nucleus of glioma cells. LncRNA PAXIP1-AS1 could upregulate the KIF14 promoter activity by recruiting transcription factor ETS1. Overexpression of lncRNA PAXIP1-AS1 enhanced migration, invasion, and angiogenesis of human umbilical vein endothelial cells in glioma by recruiting the transcription factor ETS1 to upregulate the expression of KIF14, which was further confirmed by accelerated tumor growth in nude mice. The key findings of this study highlighted the potential of the lncRNA PAXIP1-AS1/ETS1/KIF14 axis as a therapeutic target for glioma treatment, due to its role in controlling the migration and invasion of glioma cells and its angiogenesis.
ArticleNumber 486
Audience Academic
Author Yu, Hongquan
Zhao, Guifang
Zhang, Yu
Zhao, Donghai
Jiang, Hong
Qi, Ling
Wang, Weiyao
Xu, Haiyang
Author_xml – sequence: 1
  givenname: Haiyang
  surname: Xu
  fullname: Xu, Haiyang
– sequence: 2
  givenname: Guifang
  surname: Zhao
  fullname: Zhao, Guifang
– sequence: 3
  givenname: Yu
  surname: Zhang
  fullname: Zhang, Yu
– sequence: 4
  givenname: Hong
  surname: Jiang
  fullname: Jiang, Hong
– sequence: 5
  givenname: Weiyao
  surname: Wang
  fullname: Wang, Weiyao
– sequence: 6
  givenname: Donghai
  surname: Zhao
  fullname: Zhao, Donghai
– sequence: 7
  givenname: Hongquan
  surname: Yu
  fullname: Yu, Hongquan
– sequence: 8
  givenname: Ling
  surname: Qi
  fullname: Qi, Ling
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31823805$$D View this record in MEDLINE/PubMed
BookMark eNp1km9r1TAUxotM3B_9AL6RgCC-6czpn7R5I1zGpheHDp3gu3Capl1Gb3KXtMN9FT-tp7ub7g6llIaT5_md5PTZT3acdyZJXgI_BKjFuwg5L0TKQaZQVEVaPUn2oCpFKqUQOw_Wu8l-jJecC5AgnyW7OdRZXvNyL_l16l3PiJtq31pafv28YGeLH8szSBffgHWo7WBHHE1k2gwDs-4ao_WOoWvp7a3vjTPRRuY71g_Wr5A1NywYHSY7zsQxoIs62PU42wg4-sCOzwk-ejatg-mngfjs0_IECmZ-UiXOHZ4nTzsconlx9z1Ivp8cnx99TE-_fFgeLU5TXUoYU9MWoi67EomMdYuy1A1yWdQVbVSiRNM0iDVA0YqsMhUX2AEaqNEII3STHyTLDbf1eKnWwa4w3CiPVt0WfOgVhtHqwSiuq7Jp2xzbjBdtIaUuM5BZUUMtwXRArPcb1npqVqbVxtHthy3o9o6zF6r310pInpV5QYC3d4DgryYTR7WycR48OuOnqLI8KyT1vJW-fiS99FNwNKpZVeeirGT-V9UjXcC6zlNfPUPVQgDPecZ5TarDf6joac3KakpdZ6m-ZXjzwHBhcBgvoh-m-R_HbeGrhxP5M4r7CJKg2gh08DEG0yk95404dAQ7KOBqDrvahF1R2NUcdlWREx457-H_9_wG-RYANQ
CitedBy_id crossref_primary_10_1080_15476286_2023_2290771
crossref_primary_10_1016_j_cyto_2024_156663
crossref_primary_10_3389_fimmu_2023_1258344
crossref_primary_10_1007_s12032_024_02497_0
crossref_primary_10_3389_fcell_2022_846864
crossref_primary_10_1097_CM9_0000000000002722
crossref_primary_10_3389_fnmol_2021_763610
crossref_primary_10_1016_j_heliyon_2023_e22774
crossref_primary_10_1002_kjm2_12491
crossref_primary_10_1111_jcmm_16761
crossref_primary_10_3390_ncrna6040042
crossref_primary_10_1007_s12672_024_01144_4
crossref_primary_10_1016_j_brainresbull_2021_07_009
crossref_primary_10_1007_s12033_022_00448_6
crossref_primary_10_1007_s10048_024_00793_5
crossref_primary_10_3389_fimmu_2021_713757
crossref_primary_10_1371_journal_pone_0290031
crossref_primary_10_1111_jcmm_18182
crossref_primary_10_1007_s12672_024_01587_9
crossref_primary_10_3389_fonc_2021_688027
crossref_primary_10_3390_jpm11020138
crossref_primary_10_1038_s41419_023_05862_5
crossref_primary_10_1016_j_ncrna_2024_05_009
crossref_primary_10_18632_aging_203499
crossref_primary_10_3390_biomedicines10082031
crossref_primary_10_1007_s12031_022_02005_x
crossref_primary_10_1016_j_compbiomed_2021_105034
crossref_primary_10_3389_fphar_2020_586653
crossref_primary_10_1002_cbf_3921
crossref_primary_10_1002_cam4_5517
crossref_primary_10_1080_21655979_2021_1982275
crossref_primary_10_3389_fcell_2021_716462
crossref_primary_10_1186_s13048_021_00822_z
crossref_primary_10_1186_s12935_021_02168_4
crossref_primary_10_3892_etm_2024_12510
crossref_primary_10_18632_aging_202490
crossref_primary_10_2147_OTT_S276559
crossref_primary_10_1080_10641955_2022_2056194
crossref_primary_10_1186_s12935_022_02575_1
crossref_primary_10_1016_j_brainresbull_2021_08_011
crossref_primary_10_1166_jbt_2023_3253
crossref_primary_10_1016_j_biopha_2023_114477
crossref_primary_10_1016_j_omtn_2021_04_022
crossref_primary_10_1038_s41598_022_06934_w
crossref_primary_10_3389_fmolb_2021_559800
crossref_primary_10_2147_CMAR_S250284
crossref_primary_10_1016_j_bbagen_2024_130567
crossref_primary_10_1007_s13205_021_02987_2
crossref_primary_10_1080_15384101_2020_1850971
crossref_primary_10_1186_s12935_020_01649_2
crossref_primary_10_1002_ijc_34040
crossref_primary_10_1016_j_omtn_2022_03_012
Cites_doi 10.18632/oncotarget.17985
10.1002/dvdy.24125
10.1186/1476-4598-2-29
10.1038/oncsis.2017.7
10.1038/s41419-019-1477-5
10.1042/BSR20190232
10.1007/s11060-018-2951-0
10.1371/journal.pmed.1002192
10.1038/s41467-019-08679-z
10.1080/15384047.2017.1323590
10.1186/s12943-018-0812-2
10.1038/sdata.2017.117
10.1038/s41388-018-0302-4
10.1111/j.1349-7006.2003.tb01517.x
10.1038/nm.3981
10.1016/j.jphotobiol.2016.05.027
10.1158/0008-5472.CAN-10-2435
10.1084/jem.20150851
10.3389/fimmu.2017.00383
10.1002/wdev.342
10.1038/nature24014
10.1002/path.5195
10.1016/j.semcancer.2017.11.010
10.1016/j.canep.2012.08.011
10.1002/cncr.25461
10.1016/S0304-3835(00)00559-0
10.1016/S1474-4422(10)70105-8
10.1093/neuonc/noy074
10.1016/j.canlet.2018.01.041
10.1007/s12035-019-1561-y
10.1038/nrg3606
10.1038/mt.2015.170
10.1038/ni.2712
10.1158/0008-5472.CAN-10-0244
ContentType Journal Article
Copyright COPYRIGHT 2019 BioMed Central Ltd.
2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s). 2019
Copyright_xml – notice: COPYRIGHT 2019 BioMed Central Ltd.
– notice: 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s). 2019
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s13046-019-1474-7
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni Edition)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList



MEDLINE - Academic
Publicly Available Content Database
MEDLINE
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals (DOAJ)
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1756-9966
EndPage 12
ExternalDocumentID oai_doaj_org_article_0c75bdd3ad204d499c52192481891ef1
PMC6902534
A610302008
31823805
10_1186_s13046_019_1474_7
Genre Journal Article
GeographicLocations China
United States--US
Japan
GeographicLocations_xml – name: China
– name: United States--US
– name: Japan
GrantInformation_xml – fundername: National Natural Science Foundation of China
  grantid: 81201671, 81901972
– fundername: Foundation of Science and Technology Department of Jilin Province
  grantid: 20190101006JH, 20180101306JC, 20190201090JC
– fundername: ;
  grantid: 81201671, 81901972
– fundername: ;
  grantid: 20190101006JH, 20180101306JC, 20190201090JC
GroupedDBID ---
0R~
29K
2WC
4.4
5GY
5VS
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ADBBV
ADRAZ
ADUKV
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AOIJS
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
D-I
DIK
DU5
E3Z
EBD
EBLON
EBS
EJD
ESX
F5P
FYUFA
GROUPED_DOAJ
H13
HMCUK
HYE
IAO
IEA
IHR
IHW
INH
INR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
TR2
TUS
UKHRP
~8M
-5E
-5G
-A0
-BR
3V.
ACRMQ
ADINQ
C24
CGR
CUY
CVF
ECM
EIF
NPM
PMFND
7XB
8FK
AZQEC
DWQXO
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
PUEGO
5PM
ID FETCH-LOGICAL-c591t-ed4685f5afaca8da95cba09487d46765aebbaa8114d627e706af1ae18ae6e6cb3
IEDL.DBID M48
ISSN 1756-9966
0392-9078
IngestDate Wed Aug 27 01:09:51 EDT 2025
Thu Aug 21 13:54:19 EDT 2025
Sun Aug 24 03:59:30 EDT 2025
Fri Jul 25 08:04:27 EDT 2025
Tue Jun 17 21:12:46 EDT 2025
Tue Jun 10 20:49:57 EDT 2025
Thu May 22 21:22:20 EDT 2025
Thu Jan 02 22:59:15 EST 2025
Tue Jul 01 02:26:38 EDT 2025
Thu Apr 24 23:05:32 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Angiogenesis
Glioma
Migration
KIF14
PAXIP1-AS1
ETS1
Invasion
Long non-coding RNA
Language English
License Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c591t-ed4685f5afaca8da95cba09487d46765aebbaa8114d627e706af1ae18ae6e6cb3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://www.proquest.com/docview/2328365793?pq-origsite=%requestingapplication%
PMID 31823805
PQID 2328365793
PQPubID 105475
PageCount 12
ParticipantIDs doaj_primary_oai_doaj_org_article_0c75bdd3ad204d499c52192481891ef1
pubmedcentral_primary_oai_pubmedcentral_nih_gov_6902534
proquest_miscellaneous_2324921934
proquest_journals_2328365793
gale_infotracmisc_A610302008
gale_infotracacademiconefile_A610302008
gale_healthsolutions_A610302008
pubmed_primary_31823805
crossref_citationtrail_10_1186_s13046_019_1474_7
crossref_primary_10_1186_s13046_019_1474_7
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2019-12-10
PublicationDateYYYYMMDD 2019-12-10
PublicationDate_xml – month: 12
  year: 2019
  text: 2019-12-10
  day: 10
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Journal of experimental & clinical cancer research
PublicationTitleAlternate J Exp Clin Cancer Res
PublicationYear 2019
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References Z Kun-Peng (1474_CR20) 2017; 8
BJ Reon (1474_CR15) 2016; 13
S Gupta (1474_CR21) 2010; 70
P Saelee (1474_CR32) 2017; 8
J Xi (1474_CR14) 2018; 419
T Weirick (1474_CR16) 2018; 19
G Mazor (1474_CR23) 2019; 10
A Fatica (1474_CR12) 2014; 15
M Huarte (1474_CR13) 2015; 21
Y Zhang (1474_CR35) 2011; 71
G Kitange (1474_CR36) 1999; 79
S Tsutsumi (1474_CR38) 2000; 160
A Kumar (1474_CR30) 2014; 243
EC Zook (1474_CR31) 2016; 213
J Cai (1474_CR27) 2018; 140
G De Gregoriis (1474_CR28) 2017; 18
H Yu (1474_CR24) 2017; 6
Y Yan (1474_CR25) 2017; 10
S Khatun (1474_CR37) 2003; 94
S Bakas (1474_CR1) 2017; 4
O Gusyatiner (1474_CR3) 2018; 51
X Zhao (1474_CR22) 2015; 23
K Jandl (1474_CR29) 2019; 247
J Dittmer (1474_CR33) 2003; 2
QR Lu (1474_CR5) 2019; 8
SM Ayuk (1474_CR19) 2016; 161
D Li (1474_CR34) 2018; 37
M Kiran (1474_CR8) 2018
M Jansen (1474_CR4) 2010; 9
HS Venkatesh (1474_CR2) 2017; 549
1474_CR6
MA Zachariah (1474_CR7) 2018; 20
Z Peng (1474_CR9) 2018; 17
1474_CR26
Q Wang (1474_CR17) 2013; 37
Y Yu (1474_CR39) 2010; 116
G Hu (1474_CR11) 2013; 14
A Sahin (1474_CR18) 2005; 15
X Agirre (1474_CR10) 2019; 10
References_xml – volume: 8
  start-page: 71881
  issue: 42
  year: 2017
  ident: 1474_CR20
  publication-title: Oncotarget.
  doi: 10.18632/oncotarget.17985
– volume: 243
  start-page: 937
  issue: 7
  year: 2014
  ident: 1474_CR30
  publication-title: Dev Dyn
  doi: 10.1002/dvdy.24125
– volume: 2
  start-page: 29
  year: 2003
  ident: 1474_CR33
  publication-title: Mol Cancer
  doi: 10.1186/1476-4598-2-29
– volume: 6
  issue: 3
  year: 2017
  ident: 1474_CR24
  publication-title: Oncogenesis.
  doi: 10.1038/oncsis.2017.7
– volume: 10
  start-page: 246
  issue: 3
  year: 2019
  ident: 1474_CR23
  publication-title: Cell Death Dis
  doi: 10.1038/s41419-019-1477-5
– ident: 1474_CR26
  doi: 10.1042/BSR20190232
– volume: 140
  start-page: 225
  issue: 2
  year: 2018
  ident: 1474_CR27
  publication-title: J Neuro-Oncol
  doi: 10.1007/s11060-018-2951-0
– volume: 13
  issue: 12
  year: 2016
  ident: 1474_CR15
  publication-title: PLoS Med
  doi: 10.1371/journal.pmed.1002192
– volume: 79
  start-page: 407
  issue: 4
  year: 1999
  ident: 1474_CR36
  publication-title: Lab Investig
– volume: 10
  start-page: 821
  issue: 1
  year: 2019
  ident: 1474_CR10
  publication-title: Nat Commun
  doi: 10.1038/s41467-019-08679-z
– volume: 18
  start-page: 439
  issue: 6
  year: 2017
  ident: 1474_CR28
  publication-title: Cancer Biol Ther
  doi: 10.1080/15384047.2017.1323590
– volume: 19
  start-page: 199
  issue: 2
  year: 2018
  ident: 1474_CR16
  publication-title: Brief Bioinform
– volume: 17
  start-page: 61
  issue: 1
  year: 2018
  ident: 1474_CR9
  publication-title: Mol Cancer
  doi: 10.1186/s12943-018-0812-2
– volume: 4
  start-page: 170117
  year: 2017
  ident: 1474_CR1
  publication-title: Sci Data
  doi: 10.1038/sdata.2017.117
– volume: 37
  start-page: 4871
  issue: 35
  year: 2018
  ident: 1474_CR34
  publication-title: Oncogene.
  doi: 10.1038/s41388-018-0302-4
– volume: 94
  start-page: 769
  issue: 9
  year: 2003
  ident: 1474_CR37
  publication-title: Cancer Sci
  doi: 10.1111/j.1349-7006.2003.tb01517.x
– volume: 21
  start-page: 1253
  issue: 11
  year: 2015
  ident: 1474_CR13
  publication-title: Nat Med
  doi: 10.1038/nm.3981
– volume: 161
  start-page: 368
  year: 2016
  ident: 1474_CR19
  publication-title: J Photochem Photobiol B
  doi: 10.1016/j.jphotobiol.2016.05.027
– volume: 71
  start-page: 3552
  issue: 10
  year: 2011
  ident: 1474_CR35
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-10-2435
– volume: 213
  start-page: 687
  issue: 5
  year: 2016
  ident: 1474_CR31
  publication-title: J Exp Med
  doi: 10.1084/jem.20150851
– volume: 8
  start-page: 383
  year: 2017
  ident: 1474_CR32
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2017.00383
– volume: 8
  issue: 4
  year: 2019
  ident: 1474_CR5
  publication-title: Wiley Interdiscip Rev Dev Biol
  doi: 10.1002/wdev.342
– volume: 549
  start-page: 533
  issue: 7673
  year: 2017
  ident: 1474_CR2
  publication-title: Nature.
  doi: 10.1038/nature24014
– volume: 247
  start-page: 357
  issue: 3
  year: 2019
  ident: 1474_CR29
  publication-title: J Pathol
  doi: 10.1002/path.5195
– volume: 51
  start-page: 50
  year: 2018
  ident: 1474_CR3
  publication-title: Semin Cancer Biol
  doi: 10.1016/j.semcancer.2017.11.010
– volume: 37
  start-page: 79
  issue: 1
  year: 2013
  ident: 1474_CR17
  publication-title: Cancer Epidemiol
  doi: 10.1016/j.canep.2012.08.011
– volume: 116
  start-page: 5150
  issue: 22
  year: 2010
  ident: 1474_CR39
  publication-title: Cancer.
  doi: 10.1002/cncr.25461
– volume-title: Tang X
  year: 2018
  ident: 1474_CR8
– volume: 160
  start-page: 45
  issue: 1
  year: 2000
  ident: 1474_CR38
  publication-title: Cancer Lett
  doi: 10.1016/S0304-3835(00)00559-0
– volume: 9
  start-page: 717
  issue: 7
  year: 2010
  ident: 1474_CR4
  publication-title: Lancet Neurol
  doi: 10.1016/S1474-4422(10)70105-8
– volume: 20
  start-page: 1155
  issue: 9
  year: 2018
  ident: 1474_CR7
  publication-title: Neuro-Oncology
  doi: 10.1093/neuonc/noy074
– volume: 419
  start-page: 203
  year: 2018
  ident: 1474_CR14
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2018.01.041
– volume: 10
  start-page: 53
  year: 2017
  ident: 1474_CR25
  publication-title: Front Mol Neurosci
– ident: 1474_CR6
  doi: 10.1007/s12035-019-1561-y
– volume: 15
  start-page: 7
  issue: 1
  year: 2014
  ident: 1474_CR12
  publication-title: Nat Rev Genet
  doi: 10.1038/nrg3606
– volume: 23
  start-page: 1899
  issue: 12
  year: 2015
  ident: 1474_CR22
  publication-title: Mol Ther
  doi: 10.1038/mt.2015.170
– volume: 15
  start-page: 771
  issue: 5
  year: 2005
  ident: 1474_CR18
  publication-title: Int J Mol Med
– volume: 14
  start-page: 1190
  issue: 11
  year: 2013
  ident: 1474_CR11
  publication-title: Nat Immunol
  doi: 10.1038/ni.2712
– volume: 70
  start-page: 6735
  issue: 17
  year: 2010
  ident: 1474_CR21
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-10-0244
SSID ssj0061919
Score 2.4774907
Snippet Gliomas are common life-threatening cancers, mainly due to their aggressive nature and frequent invasiveness and long non-coding RNAs (lncRNAs) are emerging as...
Background Gliomas are common life-threatening cancers, mainly due to their aggressive nature and frequent invasiveness and long non-coding RNAs (lncRNAs) are...
Abstract Background Gliomas are common life-threatening cancers, mainly due to their aggressive nature and frequent invasiveness and long non-coding RNAs...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 486
SubjectTerms Analysis
Animals
Brain Neoplasms - genetics
Brain Neoplasms - pathology
Cancer
Cell Line, Tumor
Cell Nucleus - genetics
Development and progression
Endothelium
ETS1
Fluorides
Gene expression
Gene Expression Regulation, Neoplastic
Glioma
Glioma - genetics
Glioma - pathology
Gliomas
Health aspects
Human Umbilical Vein Endothelial Cells
Humans
Hybridization
KIF14
Kinesin
Kinesin - genetics
Laboratory animals
Long non-coding RNA
Mice
Migration
Neoplasm Invasiveness
Neoplasm Transplantation
Nervous system
Oncogene Proteins - genetics
Patients
PAXIP1-AS1
Promoter Regions, Genetic
Proteins
Proto-Oncogene Protein c-ets-1 - genetics
RNA
RNA, Long Noncoding - genetics
Surgery
Transcription factors
Tumors
Up-Regulation
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3di9QwEA9yD-KL-G311AiCIJRr2iRtH6vccufHcegd7FvIV9fC2R67XdF_xb_WmaZbtgj64kNfOtOSZia_mUmmM4S8yrzIhEt8bIzkMWdaxqU0aSzTMi_TQgjrhgTZM3lyyd8vxXKv1RfmhIXywGHijhKbC-Ncpl2acAf-uQWDA0EDGJqS-XoIfMDm7YKpgMEQFbByPMNkhTzaMDwAhLC5jBnHBMSZFRqK9f8JyXs2aZ4vuWeAFnfI7dFzpFUY8V1yw7f3yM1P49n4ffLrY9euKETzse3QINHPZxU9r5an5yyuvjBaaxsqcvsNxe162rTfNe6VUd06uFZNt0Lgaza0q-nqqum-aWp-UoDE9bbB7Gjao2HbwQwNrXro8QW8vO_o9nod-tp7-uF0wTj1P8Yk2_YBuVwcX7w7icfOC7EVJetj77gsRC00vEkXTpfCGg2BYJEDIZdCe2O0LiCWcjLNfZ5IXTPtWaG99NKa7CE5gO_1jwk11lkgcp5qyZMaq8tnPPWFTnIjUs8ikuwkoexYlhy7Y1ypITwppArCUyA8hcJTeUTeTI9ch5ocf2N-i-KdGLGc9nADlEyNSqb-pWQReYHKocK_qRMoqEpilzZMIYnI64EDYQGGb_X4dwNMAhbYmnEezjhhOds5eaeAaoSTjQK3t8ikACyNyMuJjE9iilzru-3Aw0sYdcYj8ijo6_TRANzgmiUiIvlMk2ezMqe0zdeh2LjEc-iMP_kf0_iU3EqHNZiC9T8kB_1665-BT9eb58Py_Q12gkd3
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1ra9RAcNEK4hfxbbTqCoIghGaT3U3ySU7p0fooRVu4b8u-EgM1Oe8h-lf8tc4ke7FB6If7cjMJk8x7ZzJDyKvMi0y4xMfGSB5zpmVcSpPGMi3zMi2EsK5vkD2RR-f8w0IswoHbOrRV7mxib6hdZ_GM_AA8f5FJAeL0dvkjxq1RWF0NKzSukxs4ugxbuvLFmHBBbtAv9gAPCRRAXB-qmqyQB2uGJUFIpMuYcWxJnPilfnz__0b6kpeadlBecknzO-R2iCXpbGD-XXLNt_fIzc-hWn6f_PnUtTWF_D62Hboo-uVkRk9ni-NTFs--MlppO8zo9muKB_i0aX9qPD2junXwq5uuRlPYrGlX0fqi6b5ran5TMJKrbYP90nSDrm5neOiwvIcensHNNx3dLlfDpntPPx7PGaf-V2i7bR-Q8_nh2fujOOxiiK0o2Sb2jstCVELDnXThdCms0ZAaFjkAcim0N0brArIrJ9Pc54nUFdOeFdpLL63JHpI9eF7_mFBjnQUg56mWPKlw3nzGU1_oJDci9SwiyY4TyoZB5bgv40L1CUsh1cA8BcxTyDyVR-TNeMlymNJxFfI7ZO-IiAO2-z-6Va2CvqrE5sI4l2mXJtxBWmghzoFcFeKbkvkKiHyBwqGGr1VHM6FmEve2YVNJRF73GGgogHyrw_cO8BJw5NYEc3-CCQpup-CdAKpgYNbqnzpE5OUIxiuxaa713bbH4SVQnfGIPBrkdXxoMOUQrCUiIvlEkidvZQppm2_9-HGJlemMP7marKfkVtprVwqefp_sbVZb_wzit4153ivpX4QiQZs
  priority: 102
  providerName: ProQuest
Title Long non-coding RNA PAXIP1-AS1 facilitates cell invasion and angiogenesis of glioma by recruiting transcription factor ETS1 to upregulate KIF14 expression
URI https://www.ncbi.nlm.nih.gov/pubmed/31823805
https://www.proquest.com/docview/2328365793
https://www.proquest.com/docview/2324921934
https://pubmed.ncbi.nlm.nih.gov/PMC6902534
https://doaj.org/article/0c75bdd3ad204d499c52192481891ef1
Volume 38
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjR1ri9NAcLkHiF_EtznPuoIgCNE89pF8EGml5U69UuoVil-W3c2mBmpy14fc_RV_rbObNFzwED80HzqTZR_z3JnMIPQ6NjSmWWB8pRjxSSiZnzIV-SxKeRollOrMJciO2cmMfJ7T-R7atbdqNnB9q2tn-0nNVst3V5fXH4HhPziGT9j7dWjDe-AUp35IbHrhPjoExcQtn56RNqgAroLr8xGASeCDT5g0Qc5bh-ioKVfN_2-ZfUNpdRMqb2io0X10rzEtcb-mhQdoz5QP0Z2zJnj-CP3-WpULDO6-ryursfB03MeT_vx0Evr9byHOpa5Ldps1tvf5uCh_SXuZhmWZwW9RVAsrGYs1rnK8WBbVT4nVNQaZudoWNn0ab6zm28khXPfywcNzGHxT4e3Fqm58b_CX01FIsLlqsnDLx2g2Gp5_OvGb1gy-pmm48U1GWEJzKmEkmWQypVpJ8BQTDgDOqDRKSZmAs5WxiBseMJmH0oSJNMwwreIn6ADWa54hrHSmAUhIJBkJclt-PiaRSWTAFY1M6KFgdxJCN3XLbfuMpXD-S8JEfXgCDk_YwxPcQ2_bVy7qoh3_Qh7Y420Rbb1t90e1WoiGfUWgOVVZFsssCkgGXqIGswdcVzB30tDkMMmXljhE_fFqKzVEn9k2bjbHxENvHIalZJi-ls3nD7AJtgJXB_O4gwn8rrvgHQGKHbsIsIuTmFEQth561YLtmzaHrjTV1uGQFGYdEw89rem1XTRIdrDdAuoh3qHkzq50IWXxw1UjZzZQHZOj_17fc3Q3cowWgQ1wjA42q615AZbdRvXQPp_zHjocDMeTac_dj_QcD8NzOvj-B6xnTQ4
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lj9MwELaWrgRcEG8CC2skEBJStHnYTnJAqAutWtqtqqUr9WYcxymRlqT0Aexf4UfwG5nJo2yEtLc99FJPItsz_mYmM54h5JVvuM8Tx9hxLJjNXCXsSMSeLbwoiLyQc52UCbITMThjn-Z8vkf-NHdhMK2ywcQSqJNC4zfyI9D8oS84iNP75Xcbu0ZhdLVpoVGJxchc_ASXbf1u-BH4-9rz-r3Zh4FddxWwNY_cjW0SJkKecpUqrcJERVzHCpycMICBQHBl4lipEPyERHiBCRyhUlcZN1RGGKFjH957g-wzH1yZDtk_7k2mpw32gzdSthIBnQxrBk-ijqO6oThauxiEBNc9sl2GSZAtTVg2DPhfLVzSi-2czUtKsH-X3KmtV9qtxO0e2TP5fXLzpI7PPyC_x0W-oHmR27pApUhPJ1067c6HU9fufnYpbEZVFdysKYYMaJb_UPi9jqo8gd8iKxYIvtmaFildnGfFN0XjCwqwvNpmmKFNN6hcG6ijVbsg2pvByzcF3S5XZoENyQwdDfsuo-ZXneibPyRn18KnR6QD6zVPCI11omGQMU8J5qRY4d5nngmVE8TcM65FnIYTUtel0bFDx7ksXaRQyIp5EpgnkXkysMjb3SPLqi7IVcTHyN4dIZb0Lv8oVgtZI4R0dMDjJPFV4jksAUdUg2UF3jFYVJFrUpjkIQqHrO7H7oBJdgV2isM0Fou8KSkQmmD6WtU3LGATsMhXi_KgRQmQotvDjQDKGtLW8t8BtMjL3TA-iWl6uSm2JQ2LYNY-s8jjSl53iwblAeahwy0StCS5tSvtkTz7WhY8FxgL99nTq6d1SG4NZidjOR5ORs_Iba88aR7YGQeks1ltzXOwHjfxi_rIUvLlulHiLxIagkg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Long+non-coding+RNA+PAXIP1-AS1+facilitates+cell+invasion+and+angiogenesis+of+glioma+by+recruiting+transcription+factor+ETS1+to+upregulate+KIF14+expression&rft.jtitle=Journal+of+experimental+%26+clinical+cancer+research&rft.au=Xu%2C+Haiyang&rft.au=Zhao%2C+Guifang&rft.au=Zhang%2C+Yu&rft.au=Jiang%2C+Hong&rft.date=2019-12-10&rft.pub=BioMed+Central+Ltd&rft.issn=0392-9078&rft.volume=38&rft.issue=1&rft_id=info:doi/10.1186%2Fs13046-019-1474-7&rft.externalDocID=A610302008
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-9966&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-9966&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-9966&client=summon